Vyome Holdings (HIND) Cash & Current Investments (2015 - 2026)
Vyome Holdings (HIND) posted quarterly Cash & Current Investments of $8.8 million for Q1 2026, up 249.73% year-over-year from $2.5 million in Q1 2025, and up 76.54% quarter-over-quarter from $5.0 million in Q4 2025.
Vyome Holdings (HIND) Cash & Current Investments (2015 - 2026) Analysis & Trends
Vyome Holdings' Cash & Current Investments history runs 12 years deep, the most recent figure standing at $8.8 million for Q1 2026.
- In Q1 2026, Cash & Current Investments rose 249.73% year-over-year to $8.8 million; the TTM figure through Mar 2026 stood at $8.8 million (up 249.73% YoY), while the FY2025 annual figure was $5.0 million, up 4789.24% from the prior year.
- Cash & Current Investments for Q1 2026 stood at $8.8 million, up from $5.0 million in the prior quarter.
- The five-year high for Cash & Current Investments was $15.5 million in Q1 2022, with the low at $12000.0 in Q2 2024.
- The 5-year median for Cash & Current Investments is $4.6 million (2023), against an average of $5.1 million.
- The sharpest annual moves came in 2024 and 2025: Cash & Current Investments tumbled 99.74% in 2024, then soared 35091.67% in 2025.
- Vyome Holdings' Cash & Current Investments stood at $4.0 million in 2022, then gained by 15.27% to $4.6 million in 2023, then plunged by 97.76% to $101904.0 in 2024, then soared by 4789.24% to $5.0 million in 2025, then jumped by 76.54% to $8.8 million in 2026.
- Business Quant data shows HIND's Cash & Current Investments at $8.8 million in Q1 2026, $5.0 million in Q4 2025, and $5.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 7.99 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 5.18 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.14 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 3.31 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 18.39 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.16 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 836.99 Mn |
| 10 | Vyome Holdings | 16.07 Mn | 8.18 Mn | 11,658.00 | 7.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.89 Mn |
| Mar 31, 2026 | 8.80 Mn |
| Dec 31, 2025 | 4.98 Mn |
| Sep 30, 2025 | 5.71 Mn |
| Jun 30, 2025 | 4.22 Mn |
| Mar 31, 2025 | 2.52 Mn |
| Dec 31, 2024 | 101,904.00 |
| Sep 30, 2024 | 800,000.00 |
| Jun 30, 2024 | 12,000.00 |
| Mar 31, 2024 | 2.48 Mn |
| Dec 31, 2023 | 4.56 Mn |
| Sep 30, 2023 | 1.55 Mn |
| Jun 30, 2023 | 4.67 Mn |
| Mar 31, 2023 | 9.08 Mn |
| Dec 31, 2022 | 3.96 Mn |
| Sep 30, 2022 | 6.25 Mn |
| Jun 30, 2022 | 11.54 Mn |
| Mar 31, 2022 | 15.46 Mn |
| Dec 31, 2021 | 22.82 Mn |
| Sep 30, 2021 | 29.29 Mn |